Urinary prostate cancer 3 test: toward the age of reason?

Urology

Department of Molecular Oncology and Transfert, Lyon Sud Hospital, Pierre-Bénite, France.

Published: February 2010

The prostate cancer 3 (PCA3) gene was discovered in 1999, on the basis of differential expression between cancer and noncancerous prostate tissue. Including the first study published in 2003, 11 clinical studies have evaluated its utility for the diagnosis of prostate cancer by measuring the number of PCA3 RNA copies in urine enriched with prostate cells. Although the sensitivity of the PCA3 test was less than that of serum prostate-specific antigen (PSA), its specificity appeared to be much better, particularly in patients with a previous negative biopsy. Recent studies also have suggested that this test could be used to predict cancer prognosis.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2009.03.046DOI Listing

Publication Analysis

Top Keywords

prostate cancer
12
cancer
5
urinary prostate
4
cancer test
4
test age
4
age reason?
4
prostate
4
reason? prostate
4
cancer pca3
4
pca3 gene
4

Similar Publications

Immunohistochemical Detection of CD147 Expression in Adenocarcinoma of the Prostate: A Case-Control Study.

Prostate Cancer

December 2024

Department of Histopathology and Cytology, Faculty of Medical Laboratory Sciences, Al-Neelain University, Khartoum, Sudan.

Prostate cancer is the most common noncutaneous malignancy among men worldwide, including in Sudan, where it represents a significant public health challenge. CD147, a transmembrane glycoprotein implicated in tumor progression, invasion, and metastasis, has shown potential as a prognostic biomarker in various cancers. This retrospective case-control study aimed to evaluate CD147 expression in prostate adenocarcinoma among Sudanese men and its association with tumor grade.

View Article and Find Full Text PDF

Background: Prostate cancer (PCa) was the most common noncutaneous cancer among Nigerian men in 2020. Despite this high incidence, documented rates may be an underestimation.

Objectives: This study aimed to determine the hospital incidence rate, trends, and characterise the clinicopathologic features, and treatment outcomes of patients with PCa in our institution.

View Article and Find Full Text PDF

Background: Transmembrane emp24 trafficking protein 3 (TMED3) is associated with the development of several tumors; however, whether TMED3 regulates the progression of prostate cancer remains unclear.

Materials And Methods: Short hairpin RNA was performed to repress TMED3 in prostate cancer cells (DU145 cells) and in a prostate cancer mice model to determine its function in prostate cancer and .

Results: In the present study, we found that TMED3 was highly expressed in prostate cancer cells.

View Article and Find Full Text PDF

Background: Prostate cancer (PCa) ranks as the second leading cause of cancer-related mortality among men. Long non-coding RNAs (lncRNAs) are known to play a regulatory role in the development of various human cancers. LncRNA MAFG-divergent transcript (MAFG-DT) was reported to play a crucial role in tumor progression of multiple human cancers, such as pancreatic cancer, colorectal cancer, bladder cancer, and gastric cancer.

View Article and Find Full Text PDF

Protomix: a Python package for H-NMR metabolomics data preprocessing.

Bioinform Adv

November 2024

Laboratory of Molecular Science and Engineering, Åbo Akademi University, Henrikinkatu 2, Turku 20500, Finland.

Motivation: NMR-based metabolomics is a field driven by technological advancements, necessitating the use of advanced preprocessing tools. Despite this need, there is a remarkable scarcity of comprehensive and user-friendly preprocessing tools in Python. To bridge this gap, we have developed Protomix-a Python package designed for metabolomics research.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!